Drugs / rhPro-UK
rhPro-UK
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03108833 | Jun 2017 → Dec 2019 | pulmonary embolism | Tasly Biopharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT07617870 | Jun 2026 → Dec 2027 expected | ischemic stroke | The First Affiliated Hospital of Zhengzhou University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07389460 | Jan 2026 → Dec 2027 expected | ischemic stroke | First Affiliated Hospital Xi'an Jiaotong University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05700591 | Jan 2023 → Mar 2024 | ischemic stroke | Tasly Biopharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05507645 | Nov 2022 → Mar 2024 | ischemic stroke, thrombotic disease | Beijing Tiantan Hospital | Completed | No outcome recorded |
| Phase 3 | NCT03578822 | Aug 2018 → Feb 2020 | ischemic stroke | Tasly Biopharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03541668 | May 2018 → Apr 2020 | ischemic stroke | Tasly Biopharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02367976 | Jan 2015 → Dec 2016 | ST-elevation myocardial infarction | Suzhou RxD Biopharmaceutical Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rhPro-UK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07389460 ↗ |
| Known as | Recombinant human prourokinase | “Recombinant human prourokinase (rhPro-UK), a novel fibrin-specific thrombolytic agent independently developed in China” NCT07617870 ↗5“Recombinant human prourokinase (rhPro-UK) is a new generation of specific plasminogen activator” PMID 38296588 ↗ Dec 2024 “intravenous recombinant human Prourokinase (rhPro-UK) in acute ischemic stroke patients” NCT07389460 ↗ “Recombinant human prourokinase (rhPro-UK) is a thrombolytic agent” PMID 37490291 ↗ Jul 2023 “Recombinant Human Pro-urokinase (rhPro-UK)” NCT05700591 ↗ |
| Known as | Recombinant human urokinase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03578822 ↗ |
| Known as | Recombinant prourokinase | “Recombinant prourokinase (rhPro-UK) is a specific plasmin activator” PMID 38907679 ↗ Aug 2024 |
| Action | Activate | “Recombinant human prourokinase (rhPro-UK) is a novel plasminogen activator” PMID 41916317 ↗ Mar 2026 |
| Modality | Protein / enzyme biologic | “Recombinant human prourokinase (rhPro-UK) is a novel plasminogen activator” PMID 41916317 ↗ Mar 2026 |
| Route | Intravenous | “intravenous rhPro-UK” PMID 41916317 ↗ Mar 2026 |